ADVERTISEMENT

Acid Reflux Drugs May Not Be Safe for Breast Cancer Patients

Acid Reflux Drugs May Not Be Safe for Breast Cancer Patients

Published
Fit
2 min read
Acid Reflux Drugs May Not Be Safe for Breast Cancer Patients

Researchers have found that acid reflux medicines prescribed to breast cancer patients may have side effects such as poorer memory and concentration.

The study, published in the Journal of Cancer Survivorship, shows an association between breast cancer survivors' use of Proton Pump Inhibitors (PPIs), and reports of problems with concentration and memory.

On an average, cognitive problems reported by PPI users were between 20 and 29 percent more severe than issues reported by non-PPI users. PPIs are sold under such brand names as Nexium, Prevacid and Prilosec, the research added.

After controlling for a variety of factors that could affect cognition - such as depression or other illnesses, types of cancer treatment, age and education - the researchers found that PPI use predicted more severe concentration and memory symptoms as well as lower quality of life related to impaired cognition.

"The severity of the cognitive problems reported by PPI users in this study was comparable to what patients undergoing chemotherapy had reported in a large observational study," said study lead author Annelise Madison from Ohio State University in the US.

For the findings, the research team conducted secondary analyses of three of Kiecolt-Glaser's earlier studies examining inflammation's connection to breast cancer treatment and survivorship.

Data from 551 women in those earlier studies, 88 of whom reported taking PPIs, were used in Madison's analysis.

The women in the previous studies had provided self-reports of PPI use and cognitive symptoms multiple times over varied periods of time depending on the design of each study.

Women in the studies looking at fatigue in newly diagnosed patients and investigating yoga's effect on inflammation and fatigue in survivors had completed a questionnaire rating the severity of their memory and concentration problems on a scale of 0 to 10 over the previous five days.

The analysis found that on average, PPI users’ concentration problems in the fatigue study were 20 percent more severe than those reported by non-PPI users.

In the yoga study, PPI users' concentration problems were 29 per cent more severe than those reported by non-PPI users. There were no differences in reported memory problems.

In the third study, which featured data from the placebo visit of a typhoid vaccine trial, reported memory problems were 28 per cent more severe in PPI users than in non-users, with no differences in reports of concentration issues.

(This story was auto-published from a syndicated feed. No part of the story has been edited by FIT .)

(This story was auto-published from a syndicated feed. No part of the story has been edited by The Quint.)

(The Quint is available on Telegram. For handpicked stories every day, subscribe to us on Telegram)

We'll get through this! Meanwhile, here's all you need to know about the Coronavirus outbreak to keep yourself safe, informed, and updated.

Liked this story? We'll send you more. Subscribe to The Quint's newsletter and get selected stories delivered to your inbox every day. Click to get started.

The Quint is available on Telegram & WhatsApp too, click to join.

Read and Breaking News at the Quint, browse for more from fit

Topics:  Quint Fit 

ADVERTISEMENT
Speaking truth to power requires allies like you.
Become a Quint Insider
25
100
200

or more

PREMIUM

3 months
12 months
12 months
Check Insider Benefits
Read More
ADVERTISEMENT
Stay Updated

Subscribe To Our Daily Newsletter And Get News Delivered Straight To Your Inbox.

Join over 120,000 subscribers!
ADVERTISEMENT
More News
×
×